In asymptomatic patients with inflammatory bowel disease (IBD) who have
tested positive for SARS-CoV-2 and have had their IBD treatment
discontinued, resumption of IBD medications may be considered after 14
days, provided that the patient has not developed symptoms of
COVID-19 (14).